PTC Therapeutics Inc PTCT

NAS: PTCT | ISIN: US69366J2006 26/04/2024

28,57 USD (+12,08%)

(+12,08%) 26/04/2024

Grafiek PTC Therapeutics Inc

Grafiek PTC Therapeutics Inc

1 dag1d 12,08%
1 week1w 10,01%
1 maand1m -1,79%
3 maanden3m 1,46%
6 maanden6m 52,45%
1 jaar1j -48,19%
5 jaar5j -25,54%

PTC Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

25 april 2024 · PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results · Persbericht

23 april 2024 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

11 april 2024 · PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results · Persbericht

28 maart 2024 · PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA · Persbericht

19 maart 2024 · PTC Therapeutics Provides Key Regulatory Updates · Persbericht

29 februari 2024 · PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

27 februari 2024 · PTC Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

22 februari 2024 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

15 februari 2024 · PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results · Persbericht

25 januari 2024 · CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure · Persbericht

Profiel PTC Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ptcbio.com

Hoofdzetel: South Plainfield, New Jersey Verenigde Staten

CEO: Stuart Peltz

Werknemers: 1.467

Aandelen PTC Therapeutics Inc

Beurswaarde: 2,19 miljard USD

Effecten: 76,70 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,45

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe